Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Behav Brain Res ; 316: 115-124, 2017 01 01.
Article in English | MEDLINE | ID: mdl-27555536

ABSTRACT

Oxidative stress and mitochondrial dysfunction play indispensable role in memory and learning impairment. Growing evidences have shed light on anti-oxidative role for melatonin in memory deficit. We have previously reported that inhibition of protein kinase A by H-89 can induce memory impairment. Here, we investigated the effect of melatonin on H-89 induced spatial memory deficit and pursued their interactive consequences on oxidative stress and mitochondrial function in Morris Water Maze model. Rats received melatonin (50 and 100µg/kg/side) and H-89(10µM) intra-hippocampally 30min before each day of training. Animals were trained for 4 consecutive days, each containing one block from four trials. Oxidative stress indices, including thiobarbituric acid (TBARS), reactive oxygen species (ROS), thiol groups, and ferric reducing antioxidant power (FRAP) were assessed using spectrophotometer. Mitochondrial function was evaluated through measuring ROS production, mitochondrial membrane potential (MMP), swelling, outer membrane damage, and cytochrome c release. As expected from our previous report, H-89 remarkably impaired memory by increasing the escape latency and traveled distance. Intriguingly, H-89 significantly augmented TBARS and ROS levels, caused mitochondrial ROS production, swelling, outer membrane damage, and cytochrome c release. Moreover, H-89 lowered thiol, FRAP, and MMP values. Intriguingly, melatonin pre-treatment not only effectively hampered H-89-mediated spatial memory deficit at both doses, but also reversed the H-89 effects on mitochondrial and biochemical indices upon higher dose. Collectively, these findings highlight a protective role for melatonin against H-89-induced memory impairment and indicate that melatonin may play a therapeutic role in the treatment of oxidative- related neurodegenerative disorders.


Subject(s)
Antioxidants/therapeutic use , Isoquinolines/toxicity , Melatonin/therapeutic use , Memory Disorders/chemically induced , Memory Disorders/drug therapy , Protein Kinase Inhibitors/toxicity , Sulfonamides/toxicity , Animals , Cytochromes c/metabolism , Disease Models, Animal , Escape Reaction/drug effects , Hippocampus/drug effects , Hippocampus/metabolism , Hippocampus/pathology , Hippocampus/ultrastructure , Hypnotics and Sedatives/therapeutic use , Lipid Peroxidation/drug effects , Male , Membrane Potential, Mitochondrial/drug effects , Mitochondria/drug effects , Mitochondria/metabolism , Rats , Rats, Wistar , Reaction Time/drug effects , Reactive Oxygen Species/metabolism , Xylazine/therapeutic use
2.
Mol Neurobiol ; 53(2): 1092-1107, 2016 Mar.
Article in English | MEDLINE | ID: mdl-25579386

ABSTRACT

Multiple sclerosis (MS) is a chronic progressive, neurological disease characterized by the targeted immune system-mediated destruction of central nervous system (CNS) myelin. Autoreactive CD4+ T helper cells have a key role in orchestrating MS-induced myelin damage. Once activated, circulating Th1-cells secrete a variety of inflammatory cytokines that foster the breakdown of blood-brain barrier (BBB) eventually infiltrating into the CNS. Inside the CNS, they become reactivated upon exposure to the myelin structural proteins and continue to produce inflammatory cytokines such as tumor necrosis factor α (TNFα) that leads to direct activation of antibodies and macrophages that are involved in the phagocytosis of myelin. Proliferating oligodendrocyte precursors (OPs) migrating to the lesion sites are capable of acute remyelination but unable to completely repair or restore the immune system-mediated myelin damage. This results in various permanent clinical neurological disabilities such as cognitive dysfunction, fatigue, bowel/bladder abnormalities, and neuropathic pain. At present, there is no cure for MS. Recent remyelination and/or myelin repair strategies have focused on the role of the neurotrophin brain-derived neurotrophic factor (BDNF) and its upstream transcriptional repressor methyl CpG binding protein (MeCP2). Research in the field of epigenetic therapeutics involving histone deacetylase (HDAC) inhibitors and lysine acetyl transferase (KAT) inhibitors is being explored to repress the detrimental effects of MeCP2. This review will address the role of MeCP2 and BDNF in remyelination and/or myelin repair and the potential of HDAC and KAT inhibitors as novel therapeutic interventions for MS.


Subject(s)
Brain-Derived Neurotrophic Factor/metabolism , Gene Expression Regulation , Methyl-CpG-Binding Protein 2/metabolism , Multiple Sclerosis/genetics , Multiple Sclerosis/therapy , Myelin Sheath/pathology , Wound Healing/genetics , Animals , Humans
3.
Adv Pharmacol Sci ; 2015: 507151, 2015.
Article in English | MEDLINE | ID: mdl-26064103

ABSTRACT

Background. Heparin, used clinically as an anticoagulant, also has anti-inflammatory properties. The purpose of this systematic review was to provide a comprehensive review regarding the efficacy and safety of heparin and its derivatives as anti-inflammatory agents. Methods. We searched the following databases up to March 2012: Pub Med, Scopus, Web of Science, Ovid, Elsevier, and Google Scholar using combination of Mesh terms. Randomized Clinical Trials (RCTs) and trials with quasi-experimental design in clinical setting published in English were included. Quality assessments of RCTs were performed using Jadad score and Consolidated Standards of Reporting Trials (CONSORT) checklist. Results. A total of 280 relevant studies were reviewed and 57 studies met the inclusion criteria. Among them 48 studies were RCTs. About 65% of articles had score of 3 and higher according to Jadad score. Twelve studies had a quality score > 40% according to CONSORT items. Asthma (n = 7), inflammatory bowel disease (n = 5), cardiopulmonary bypass (n = 8), and cataract surgery (n = 6) were the most studied disease condition. Forty studies use unfractionated heparin (UFH) for intervention; the remaining studies use low molecular weight heparin (LMWH). Conclusion. Despite the conflicting results, heparin seems to be a safe and effective anti-inflammatory agent; although it is shown that heparin can decrease the level of inflammatory biomarkers and improves patient conditions, still more data from larger rigorously designed studies are needed to support use of heparin as an anti-inflammatory agent in clinical setting. However, because of the association between inflammation, atherogenesis, thrombogenesis, and cell proliferation, heparin and related compounds with pleiotropic effects may have greater therapeutic efficacy than compounds acting against a single target.

4.
Behav Brain Res ; 228(2): 432-9, 2012 Mar 17.
Article in English | MEDLINE | ID: mdl-22209852

ABSTRACT

Neurohormones such as testosterone (TE) are important in modulation of learning and memory. In the present study, we investigated the interactive effects of pre-training bilateral intra-hippocampal infusions of testosterone and H-89, a selective PKAII inhibitor, on spatial acquisition in the Morris water maze (MWM). Different doses of TE (20, 40 and 80 µg/side) and H-89 (5 and 10 µM/side) were administered 30 min before start of the training each day. Control animals received bilateral intra-hippocampal infusions of DMSO as vehicle for TE and H-89. Animals were trained for 4 days and each day included one block of four trials. The results of this study showed that bilateral infusion of TE (40 and 80 µg/side) or H-89 (10 µM/side) impaired spatial learning as indicated by significant increases in escape latency and traveled distance compared to the control group. Although pre-training bilateral infusions of a low concentration of either TE (20 µg/side) or H-89 (5 µM/side) into the CA1 region of the hippocampus did not affect learning capabilities, but the combination of the low doses of the drugs led to significant deficits in spatial acquisition. Overall, our data suggest that spatial acquisition was affected by PKAII inhibition or TE administration. Moreover, when co-administered, these drugs had a negative synergistic impact on acquisition.


Subject(s)
Androgens/pharmacology , Isoquinolines/pharmacology , Maze Learning/drug effects , Protein Kinase Inhibitors/pharmacology , Space Perception/drug effects , Sulfonamides/pharmacology , Testosterone/pharmacology , Analysis of Variance , Animals , Dose-Response Relationship, Drug , Escape Reaction/drug effects , Hippocampus/drug effects , Hippocampus/physiology , Locomotion/drug effects , Male , Microinjections , Rats , Rats, Wistar , Reaction Time/drug effects , Swimming/psychology , Time Factors
5.
Basic Clin Pharmacol Toxicol ; 109(5): 381-6, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21668649

ABSTRACT

Diabetic neuropathy (DN) is the most common peripheral neuropathy and long-term complication of diabetes. In view of the pathological basis for the treatment of DN, it is important to prevent nerve degeneration. Most of the current treatment strategies are symptomatic therapies. In this study, we evaluated the effectiveness of magnesium-25, carrying porphyrin-fullerene nanoparticles, on diabetes-induced neuropathy. Previous studies have suggested that dorsal root ganglion (DRG) neurons comprise a specific target and may be responsible for the known complications of DN. Experimental DN was induced by intraperitoneal injection of streptozotocin (STZ) (45 mg/kg). Different forms of magnesium including (25)Mg-PMC16, (24)Mg-PMC16 and MgCl(2) were administered intravenously in equal dose (0.5 LD(50)) at 48-hr intervals before STZ injection. Peripheral nerves were studied after 2 months of diabetes in groups using qualitative approaches, morphometric analysis of DRG neurons and motor function tests. We showed that STZ-induced DN caused morphological abnormalities in DRG neurons comprising changes in area, diameter and number of A and B cells as well as motor dysfunction in DN. Moreover, our findings indicated that administration of (25)Mg-PMC16 as a magnetic form of Mg improved morphological abnormalities and motor dysfunctions significantly, whereas other forms of Mg were ineffective.


Subject(s)
Diabetic Neuropathies/drug therapy , Diabetic Neuropathies/pathology , Fullerenes/administration & dosage , Ganglia, Spinal/drug effects , Magnesium/administration & dosage , Porphyrins/administration & dosage , Animals , Biomarkers , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/pathology , Dose-Response Relationship, Drug , Drug Delivery Systems , Male , Metal Nanoparticles/chemistry , Neurons/pathology , Oxidative Stress/drug effects , Peripheral Nerves/drug effects , Peripheral Nerves/pathology , Rats , Streptozocin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL